CClinicalTrials.gg
CompletedNCT00814476CareLinkUpdated Jul 10, 2013

The Effects of Regular Home Use Vs Diabetic Team- Supported Use of the Medtronic CareLink Therapy Management System.

A Phase 4 interventional study of Medtronic CareLink therapy management system and regular home use and Medtronic CareLink Therapy Management in Type 1 Diabetes, sponsored by Rabin Medical Center. Completed at 1 site in Israel. Open to participants aged Up to 35 Years. Per ClinicalTrials.gov, last updated 2013-07-10.

Sponsored by Rabin Medical Center · Phase 4, Interventional, and Supportive care

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
Up to 35 Years
Sex
All
01

Study summary

Randomized, two arms, controlled, open study comprised of two consecutive segments. At the first segment that will last during the first 4 months of the study, patients will be randomized to the Care link treated group or non Care link treated group. At this segment of the study the usage of the Care link system will be accompanied by the diabetic team, through at least monthly contact via the Internet initiated by the diabetic team. At the second segment of the study, during the following 4 months, both groups will use the Care link System, home-use, without support initiated by the diabetic team.

Read the detailed description

A randomized, two arms, controlled, open study in order to compare the efficacy, short and long term effects of regular home-use Vs diabetic team- supported use of the Medtronic CareLink therapy management system in patients with diabetes.

Primary objective:

To assess the efficacy, short term (4 months) and long term (8 months) effects of using the Medtronic CareLink® Therapy Management System for Diabetes on the following parameters:

  1. Metabolic control as expressed by HbA1c.
  2. Hypoglycemic events- number and severity of episodes.
  3. DKA and ketosis events- number and severity of episodes.
  4. Patient's satisfaction and quality of life measured by treatment satisfaction and quality of life questionnaires.
  5. 7 points glucose profile.

Secondary objective:

To compare the efficacy of 4 months treatment using the CareLink® Therapy Management System, accompanied with intensive contact (at least once a month) initiated by diabetic team via the internet/electronic mail Vs home use treatment - without monthly contact initiated by the diabetic team

Study design:

The study will be comprised of two consecutive segments. At the first segment that will last during the first 4 months of the study, patients will be randomized to the CareLink treated group or non CareLink treated group. At this segment of the study the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. At the second segment of the study, during the following 4 months, both groups will use the CareLink system, home-use, without support initiated by the diabetic team.

02

Conditions studied

  • Type 1 Diabetes

Keywords

  • Medtronic CareLink
  • therapy management
  • diabetes
  • insulin pump
  • Blood glucose monitor
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 70 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Rabin Medical Center is the lead sponsor of 385 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Type 1 diabetes diagnosed at least 6 months prior to study entry
  2. Current treatment with Medtronic 722 /712 external insulin pump systems
  3. Treatment with insulin pump at least 3 month prior to study entry
  4. An internet access from patient's home
  5. Age 0-35 years old
  6. HbA1c>7.8
  7. Signing inform consent forms

Exclusion criteria

Exclusion Criteria:

  1. Any significant disease or conditions, including psychiatric disorders that in the opinion of the investigator are likely to effect his compliance or ability to complete the study
  2. Patients participating in other device or drug studies
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    2

    Regular treated group in the first segment and CareLink treated group in the second segment

    Other: regular home use and Medtronic CareLink Therapy Management

  • Experimental
    1. CareLink team supported group

    CareLink team supported group

    Other: Medtronic CareLink therapy management system

Interventions

  • OtherMedtronic CareLink therapy management system

    At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team

  • Otherregular home use and Medtronic CareLink Therapy Management

    At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.

06

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: At Baseline and every 4 month after

Secondary outcomes

  1. Hypoglycemic events

    Time frame: will be recorded through the whole study period

  2. DKA and ketosis events

    Time frame: will be recorded through the whole study period

  3. Patient's satisfaction and quality of life questionnaire

    Time frame: At baseline visit and every 4 months after

  4. 7 points glucose profile

    Time frame: Will be recorded 2 days before baseline visit and every 4 months after

07

Study locations

1 site
  • Schnider children medical center
    Petach-Tikva, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00814476
Lead sponsor
Rabin Medical Center
Responsible party
Sponsor
First posted
Dec 24, 2008
Start date
Jan 2009
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Jul 10, 2013

Study contacts

Moshe Phillip, Professor
principal investigator · Rabin Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion